Skip to main
AAPG

AAPG Stock Forecast & Price Target

AAPG Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ascentage Pharma Group has demonstrated significant commercial success with olverembatinib, achieving RMB 217.4 million (approximately US$30.3 million) in sales during the first half of 2025, reflecting a robust year-over-year growth of about 93%. The company's strategic expansion into approximately 867 hospitals and the onboarding of additional direct-to-patient pharmacies and hospitals have enhanced its market penetration, particularly in Tier 1 and 2 oncology centers. Furthermore, the favorable market dynamics for Chinese biotech, underscored by a 58% year-to-date performance of a China Biotech ETF, suggest a positive investment climate, potentially benefiting Ascentage Pharma's trajectory in the biotech sector.

Bears say

Ascentage Pharma Group's stock outlook is negatively impacted by persistent pressure from volume-based procurement programs, which, while exempting innovative therapies during early commercialization, may still contribute to margin erosion and slowing revenue growth due to aggressive NRDL repricing cycles. Additionally, failures to meet primary endpoints in pivotal studies and declining response rates for its therapies hinder its global expansion potential, particularly affecting its competitive positioning in a less competitive landscape following setbacks in clinical trials. Furthermore, slower adoption rates in China for Olverembatinib, coupled with global studies that do not adequately differentiate the drug from existing treatments, pose significant challenges to the company's growth and overall financial health.

AAPG has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ascentage Pharma Group International and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ascentage Pharma Group International (AAPG) Forecast

Analysts have given AAPG a Buy based on their latest research and market trends.

According to 4 analysts, AAPG has a Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $48.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $48.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ascentage Pharma Group International (AAPG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.